- Treatment of pulmonary arterial hypertension (World Health Organization (WHO) Group 1) to improve exercise capacity.
- Treatment of pulmonary arterial hypertension (PAH) (WHO Group 1) to improve exercise capacity.
- Treatment of pulmonary arterial hypertension (PAH) (WHO Group1) to improve exercise capacity.
- Treatment of pulmonary arterial hypertension (PAH) (WHO Group 1) to diminish symptoms associated with exercise.
- For patients who require transition from Flolan, to reduce the rate of clinical deterioration.
- Treatment of pulmonary arterial hypertension (PAH) (WHO Group 1) to improve exercise ability.
- Treatment of pulmonary arterial hypertension (PAH) (WHO Group 1) to improve a composite endpoint consisting of exercise tolerance, symptoms (New York Heart Association (NYHA) Class) and lack of deterioration.
Uptravi:
- Treatment of pulmonary arterial hypertension (PAH) (WHO Group 1) to delay disease progression and reduce the risk of hospitalization for PAH.